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Abstract
Small cell lung cancer (SCLC) is an aggressive tumor type with early dissemination and distant metastasis capacity. Even 
though optimal chemotherapy responses are observed initially in many patients, therapy resistance is almost inevitable. 
Accordingly, SCLC has been regarded as an archetype for cancer stem cell (CSC) dynamics. To determine the immune-
modulatory influence of CSC in SCLC, this study focused on the characterization of  CD44+CD90+ CSC-like subpopulations 
in SCLC. These cells displayed mesenchymal properties, differentiated into different lineages and further contributed to 
 CD8+ cytotoxic T lymphocytes (CTL) responses. The interaction between  CD44+CD90+ CSC-like cells and T cells led to 
the upregulation of checkpoint molecules PD-1, CTLA-4, TIM-3, and LAG3. In the patient-derived lymph nodes,  CD44+ 
SCLC metastases were also observed with T cells expressing PD-1, TIM-3, or LAG3. Proliferation and IFN-γ expression 
capacity of TIM-3 and LAG3 co-expressing CTLs are adversely affected over long-time co-culture with  CD44+CD90+ CSC-
like cells. Moreover, especially through IFN-γ secreted by the T cells, the CSC-like SCLC cells highly expressed PD-L1 
and PD-L2. Upon a second encounter with immune-experienced, IFN-γ-stimulated CSC-like SCLC cells, both cytotoxic 
and proliferation capacities of T cells were hampered. In conclusion, our data provide evidence for the superior potential of 
the SCLC cells with stem-like and mesenchymal properties to gain immune regulatory capacities and cope with cytotoxic 
T cell responses. With their high metastatic and immune-modulatory assets, the CSC subpopulation in SCLC may serve as 
a preferential target for checkpoint blockade immunotherapy.
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Introduction
Small cell lung cancer (SCLC) is a neuroendocrine malig-
nancy which constitutes approximately 13% of lung can-
cers worldwide [1–3]. The patients commonly benefit 
from first-line chemotherapy; however, recurrence occurs 
very early in most SCLC cases [4, 5]. The development 
of chemoresistance subsequent to disease progression and 
the distant metastases critically limit overall survival [6]. 
Theoretically, chemotherapy-resistant cancer stem cells 
(CSCs), which constitute a very minor subpopulation, 
are responsible for drug resistance and aggressiveness in 
SCLC [7–9]. CSCs are frequently identified with mesen-
chymal markers such as CD44, CD90, CD87, and CD133 
[9–11]. Accordingly, with its multipotent neuroendocrine 
origin and superior dissemination capacity, SCLC has 
been acknowledged as an archetype for CSC research [9]. 
Nevertheless, even though the immune regulatory capaci-
ties of CSCs are well-acknowledged, their influence on 
the anti-tumor immunity in SCLC remains to be better 
elucidated.
Stem cells (SCs), undifferentiated cells with self-renewal 
capacity, are responsible for regeneration and located in stem 
cell niches to maintain their characters and numbers [12]. 
CSCs similar to tissue SCs are programmed to protect them-
selves from external threats by commonly expressing ABC 
transporters against cytostatic/cytotoxic drugs and down-
regulation of MHC class I or NKG2D ligands to protect 
themselves against anti-tumor reactions [13]. In order to 
modulate local immune responses, CSCs have the capacity 
to secrete anti-inflammatory soluble factors such as IL-10, 
IL-13, Galectin-3, GDF-15, Transforming growth factor 
(TGF)- β 1/2, prostaglandin E2 (PGE2) [14, 15]. In further 
detail, CSCs regulate monocyte differentiation by producing 
macrophage inhibitor cytokine 1 (MIC1) which in turn drive 
differentiation of monocytes toward the tumor-promoting 
type of macrophages or by expressing CD200 to inhibit mac-
rophage activation together with CD47 to block phagocyto-
sis [15–18]. Furthermore, CXCL12 secreted by CSCs recruit 
regulatory myeloid cells into the tumor microenvironment 
consisting of MDSCs, suppressive dendritic cells, and Tregs 
[14]. Expression of IDO from CSCs leads to inhibition of 
T cell proliferation and skew Th2 type immune responses 
which are more favorable for TME than destructive Th1 
type [19]. In addition to common PD-L1 expression, CSCs 
from some cancer types were shown to express Galectin-3, 
a ligand of LAG3, Galectin-9, a ligand of TIM-3, and even 
the expression of CTLA-4 and TIM-3 receptors indicating 
a close relationship between CSCs and immune checkpoint 
molecules [20–22]. More interestingly,  CD44+ stem cells 
emerged adaptive immune resistance by engaging CTLA-4 
receptor on T cells upon acquiring CD80 expression [23].
In response to inflammatory mediators such as interferon 
(IFN)-γ, which is the primary mediator of T cell-mediated 
anti-tumor immunity, cancer cells initiate an adaptive (sec-
ondary) resistance program to survive anti-tumor immune 
responses [24, 25]. In this regard, they upregulate regulatory 
ligands which directly suppress the activated T cells through 
co-inhibitory receptors such as programmed death-1 (PD-
1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), 
T-cell immunoglobulin mucin-3 (TIM-3) and lymphocyte-
activation gene 3 (LAG3) [24, 26]. Moreover, high surface 
levels of inhibitory receptors indicate a hyporesponsive state 
where the cytotoxicity against cancer cells is impaired [27]. 
Accordingly, blockade of the interaction between PD-1 and 
its ligands, PD-L1 and PD-L2, is one of the most successful 
cancer immunotherapy modalities, especially in melanoma, 
renal cell cancer, and non-small cell lung cancer [28]. Nev-
ertheless, the checkpoint blockade therapies are essentially 
successful toward immunogenic tumors which are highly 
infiltrated by  CD8+ cytotoxic T lymphocytes (CTL) [29]. 
SCLC has been regarded as an immunogenic malignancy 
since it displays a high mutation burden and bears many neo-
antigens [30, 31]. In addition, autoimmune paraneoplastic 
syndromes are common in SCLC patients [31]. Even though 
immune infiltration is limited in primary SCLC tumors, in 
metastatic lymph nodes, the interaction between SCLC cells 
and T cells is almost inevitable. Nevertheless, clinical trials 
reported a limited efficacy for targeting the PD-1/PD-L1 axis 
in SCLC patients [32].
This study aims to characterize the CSC-like subpopula-
tions within SCLC cells and to determine their influence 
on CTL responses. Here,  CD44+CD90+ cells in SCLC dis-
played mesenchymal and stemness properties which facili-
tate lymph node metastasis. Intriguingly, these CSC-like 
subpopulations maintained immune responses which lead to 
the upregulation of multiple inhibitory receptors on  CD8+ T 
cells. Moreover, they acquired immune-modulatory capaci-
ties, partly through PD-L1 and PD-L2 molecules, upon 
exposure to immune reactions and IFN-γ.
Materials and methods
Cell culture and isolation of SCLC subpopulations
SCLC-21H, NCI-H82 (DSMZ), and NCI-H69 (ATCC, LGC 
Promochem) SCLC cell lines were maintained as suspen-
sion cultures in complete H-glucose DMEM (SCLC-21H) 
or RPMI 1640 medium containing 20% fetal bovine serum 
(FBS), penicillin (100 U/mL), and streptomycin (100 µg/
mL) (Lonza) at 37 °C under a 5%  CO2 atmosphere. The 
subpopulations of NCI-H82 and NCI-H69 (H82Adh and 
H69Adh, respectively) were established by long-term serial 
passaging of the cells that adhered onto the culture flask. 
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H69Sc cells were isolated from the H69Adh subpopulation 
through CD44 positive selection by magnetic-activated cell 
sorting (MACS) (Miltenyi) which was followed by fluores-
cence-activated cell sorting (FACS) of  CD44+CD90+ cells. 
For certain experiments, SCLC cells were treated with 
150 ng/mL recombinant IFN-γ (R&D Biosystems) for 24 
or 48 h. Peripheral blood mononuclear cells (PBMC) were 
isolated from healthy donors’ blood samples (Hacettepe Uni-
versity Local Ethics Committee, approval no. GO 17/503) 
by density gradient centrifugation (Ficoll 1.077; GE Health-
care). PBMC cultures were maintained in complete RPMI 
1640 medium with 10% FBS.
Flow cytometry and FACS
The monoclonal antibodies (mAb) anti-human-CD44 
(BJ18), -CTLA-4 (L3D10), -LAG3 (11C3C65), -PD-1 
(EH12.2H7), -PD-L2 (24F.10C12), -TIM-3 (F38-2E2) (Bio-
Legend, USA); CD90 (5E10) (Thermo Fisher Scientific); 
CD4 (SK3), CD8 (SK1), CD25 (BC96) (Sony Biotechnol-
ogy); CD107a (H4A3), CD137 (4B4-1), CD69 (FN50) (BD 
Biosciences) were used in immunophenotyping analyses 
and FACS. The percentage of positive cells was determined 
in comparison with the isotype-matched antibody controls. 
For cell isolation and purification, PBMC were labeled with 
anti-CD8 and -CD56 antibodies, and cytotoxic T cells were 
sorted as  CD56−CD8+ lymphocytes with a purity of > 98%. 
For different assays,  CD8+ T cells were purified from the 
co-cultures established with SCLC cells according to their 
TIM-3 and LAG3 expression (TIM-3+LAG3+ and TIM-
3−LAG3− populations). Flow cytometric immunophenotyp-
ing and cell sorting were performed on a FACSAria II (BD).
Cell differentiation assays
Adipocyte, osteocyte, and chondrocyte differentiation 
capacities of SCLC cells were tested with commercial dif-
ferentiation kits (StemPro, Thermo Fisher Scientific) in 
accordance with the manufacturer’s recommendations. Fol-
lowing the 21-day culture in differentiation media, which 
were refreshed every 3 days, the cells were fixed with 4% 
paraformaldehyde and stained with Oil Red O, Alizarin red, 
and methylene blue which designate adipogenic, osteogenic, 
and chondrogenic differentiation, respectively.
Migration assay
SCLC cells (2 ×  105/100 µL) were resuspended in 1% FBS-
containing RPMI 1640 medium and were seeded into the 
upper chamber of the transwell with 8 µm pore polycarbon-
ate membrane insert (Corning), whereas the bottom chamber 
was filled with 10% FBS-containing culture medium. After 
16 h of incubation at 37 °C with 5%  CO2, the cells found in 
the lower chamber and the cells adhered to the bottom of the 
membrane were stained with Giemsa and counted under a light 
microscope.
Polarization analysis
SCLC cells were incubated for 16 h on chamber slides (BD) 
coated with fibronectin (Sigma-Aldrich) and, then, fixed in 
4% paraformaldehyde and permeabilized with 0.1% Triton 
X-100 (Sigma-Aldrich) in PBS, blocked with 10% BSA 
(Sigma-Aldrich) for one hour. Following the staining with 
phalloidin-iFluor 488 reagent and DAPI (Abcam), the slides 
were mounted; micrographs were taken under a fluorescent 
microscope and processed by ImageJ software (NIH).
Transcriptomic analyses 
with next generation sequencing (NGS)
Total RNA was isolated (RNeasy, QIAGEN) from human 
pulmonary alveolar epithelial cells (PAEpiC) type II cells 
(Sciencell), SCLC-21H, NCI-H82, NCI-H69, H82Adh, 
H69Adh, H69Sc, mesenchymal stem cells (MSC) (ATCC, 
LGC Promochem) or from the SCLC cells after 24 h of 
IFN-γ treatment. Then, barcoded cDNA libraries were 
generated from 10 ng of total RNA by VILO Superscript 
cDNA synthesis kit (Thermo Fisher Scientific). Ultra-
high multiplex PCR was performed with Ion AmpliSeq™ 
Human Gene Expression Chef Ready Kit (Thermo Fisher 
Scientific). The libraries were obtained (Ion Chef, Thermo 
Fisher Scientific) and clonally amplified by emulsion PCR 
(Ion PI Hi-Q OT2 200 Kit, Thermo Fisher Scientific) on an 
Ion Torrent OneTouch2 instrument. The templated libraries 
were sequenced on an Ion Proton semiconductor sequencing 
system. The data were processed by Torrent Suite analysis 
pipeline and raw reads were mapped to the human genome 
assembly hg19 AmpliSeq Transcriptome version by Tor-
rent mapping alignment software and normalized according 
to the "read per millions" method. Differentially expressed 
genes (DEG) were determined with DESeq2, the changes 
more than eightfold were considered as significant. The 
genes were clustered according to the Kyoto encyclopedia 
of genes and genomes (KEGG) pathway enrichment analy-
ses or Gene Ontology (GO) pathways that defines functional 
characteristics of the samples.
Co‑cultures
Co-cultures were established with the SCLC cells (2.5 ×  104) 
and PBMC at a 1:4 ratio in the presence of anti-CD3 
mAb (25 ng/mL, HIT3a) in U-bottom 96-well plates. At 
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different time points of incubation, either the SCLC cells 
were detached by accutase treatment (BioLegend) or the 
PBMC found in suspension were collected for further analy-
ses. To test the effect of soluble factors, conditioned media 
are collected after 48 h of culture and used in co-cultures at 
a 1:1 ratio. The SCLC cells pretreated with IFN-γ were also 
used in the co-cultures or IFN-γ neutralizing mAb (5 μg/mL, 
B27) or isotype-matched control IgG (5 μg/mL) were added 
to certain experimental setups.
Flow cytometric proliferation analysis
PBMC or  CD8+ T cells purified according to TIM-3 and 
LAG3 expression were resuspended in serum-free RPMI 
1640 (5 ×  106 cells/mL) and stained with 5 μM eFluor670 
(eBioscience) or carboxyfluorescein succinimidyl ester 
(CFSE, Invitrogen). Following several washing steps with 
complete medium, PBMCs were used in co-cultures. Fol-
lowing 96 h,  CD8+ T cells were gated and their prolifera-
tion was assessed by flow cytometry according to eFluor670 
dilution. Alternatively, the purified  CD8+ cells were further 
stimulated with anti-CD3/CD28 beads (1:1 bead-to-cell 
ratio, Dynabeads, Thermo Fisher Scientific) or with anti-
CD28 (2 µg/mL) in an anti-CD3 (2 µg/mL) coated plate for 
72 h.
Multi‑analyte ELISA array
Interleukin (IL)-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, per-
forin, sFASL, granzyme A, and granzyme B concentration 
secreted into the PBMC:SCLC co-cultures was determined 
from the supernatants collected at 96 h by a flow cytometry-
based enzyme-linked immunosorbent assay (ELISA) array 
(LEGENDplex™ Human CD8/NK Panel, BioLegend). The 
amount of cytokines was analyzed according to mean fluo-
rescence intensity (MFI) values of the samples and stand-
ards by using the data analysis software supplied by the 
manufacturer.
Tumor formation capacity of SCLC cells
Eight-week-old CD1-nude mice (Kobay A.Ş., Turkey) were 
used with ethical approval from the local ethics committee 
(Doc. Nr.:251). Parental (5 ×  105, 2 ×  106, and  107 cells/100 
μL) and adherent subpopulations of SCLC cells (5 ×  105 and 
2 ×  106/100 μL) were dispersed in serum-free RPMI 1640 
medium and injected subcutaneously. Parental cells and their 
adherent subpopulations were inoculated on the right and the 
left sides, respectively, of the mice. The tumor growth was 
followed for 6 weeks.
Immunohistochemistry
Sections (4 μm thick) from archived paraffin-embedded pri-
mary tumor and metastatic lymph node specimens of SCLC 
patients were taken and placed on polylysine microscope 
slides. Following deparaffinization, dehydration, and block-
ing of endogenous peroxidase activity, the tissue sections 
were incubated with primary antibodies, anti-CD3 (predi-
luted; 2GV6, Ventana), -CD44 (1/50 dilution; 156-3C11, 
Leica), -PD-1 (1/250 dilution; EH12.2H7, BioLegend), 
-TIM-3 (1/1500 dilution; OTI2E2, Origene), and -LAG3 
(1/625 dilution; EPR4392, Abcam). After washing steps, 
incubations with appropriate secondary antibodies, strepta-
vidin–biotin complex, horseradish peroxidase (HRP), and 
3,3′-Diaminobenzidine (DAB) chromogen were performed. 
Immunohistochemical staining was observed and docu-
mented by conventional light microscopy.
Statistical analysis
The results were obtained from at least three independent 
experiments. The data are presented as mean with standard 
deviation (SD) or standard error (SE). Mann–Whitney U 
test, Student’s paired or unpaired t-test, ANOVA, or Chi-
square tests were used where appropriate to show the statisti-
cal differences. An associated P-value lower than 0.05 was 
considered to be statistically significant.
Results
Stem‑like SCLC populations are characterized 
with mesenchymal properties
In vitro, primary SCLC cells and established cell lines 
such as SCLC-21H, NCI-H82, and NCI-H69 tend to form 
aggregates and grow in suspension [33, 34]. The relation-
ship between adherence and stemness has been previously 
reported in SCLC [33]. When grown in contact with the 
surface of culture flasks, adherent subpopulations of NCI-
H69 and NCI-H82 cell lines emerged and maintained as 
monolayer cultures, H69Adh, and H82Adh (Supplementary 
Fig. 1). These adherent cells grew in tight clusters and gave 
rise to loosely adherent cells (Supplementary Fig. 1) which 
were viable and remained in suspension (data not shown). In 
accordance with the literature, both suspension and adherent 
SCLC cells used in our study commonly expressed CD90, 
whereas CD44 expression was restricted to a minor subpop-
ulation (Fig. 1a, b). In H69Adh, a group of cells was clearly 
identified with CD90 and CD44 co-expression (Fig. 1a, b). 
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These  CD44+CD90+ cells were further purified as H69Sc 
subpopulation and maintained in vitro (Fig. 1b and Sup-
plementary Fig. 1).
Next, the parental SCLC cell lines (SCLC-21H, NCI-
H82, NCI-H69) and their derivatives (H82Adh, H69Adh, 
and H69Sc) were compared in terms of adhesion and 
migration properties, molecular signatures and mesenchy-
mal stem-like features. There was no significant difference 
between the migratory capacity of parental cell lines grown 
in suspension or their adherent subpopulations; however, 
H69Sc cells displayed a significantly higher (~ 4.5 fold) 
number of migrated cells than its parental NCI-H69 and 
H69Adh cells (Fig. 1c). When in contact with the fibronec-
tin-coated surface as a common component of the extracel-
lular matrix, adherent populations gained greater surface 
area than suspension cells (A.U., SCLC-21H, 2061 ± 687; 
NCI-H82 4917.1 ± 1639; NCI-H69, 2380 ± 660.1; H82Adh, 
8199.4 ± 2472.2; H69Adh, 15,584 ± 5896.2; H69Sc, 
15,469.9 ± 4896.4). Even though both H69Adh and H69Sc 
covered similar surface area and displayed polarized assem-
bly of actin filaments, H69Adh was identified with explicit 
directionality (Fig. 1d).
Fig. 1  Characterization of SCLC subpopulations with stem-like and 
mesenchymal properties. a Percentage distribution and b representa-
tive flow cytometry plots of SCLC cell populations according to 
CD44 and CD90 expression are shown. c Migration toward high FBS 
gradient and d polarization on fibronectin substratum are given for 
different SCLC subpopulations. Representative micrographs for the 
polarization of NCI-H69, H69Adh and H69Sc cells are shown (scale, 
10 µm). Heatmap analyses e for global transcriptomics data and f for 
the genes related to mesenchymal cells and stemness in NCI-H69 
subpopulations, alveolar epithelial cell type II (AEC II), and mesen-
chymal stem cells (MSC). g Adipogenic, chondrogenic and osteo-
genic differentiation capacities of NCI-H69, H69Adh and H69Sc 
cells. Representative micrographs obtained with oil red O, methylene 
blue, and Alizarin red staining are demonstrated
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Compared to primary type II alveolar epithelial cells 
(AEC), the transcriptome data obtained from the SCLC cells 
represented a significantly altered gene expression profile 
with a high variance ratio indicating the distinctions among 
the cell lines and their derivatives (Supplementary Fig. 2). 
Among NCI-H69, H69Adh, and H69Sc high numbers of 
differentially expressed genes (DEGs) were determined 
(> eightfold DEGs, NCI-H69 vs. H69Adh, 2436; NCI-H69 
vs. H69Sc, 4397; H69Adh vs. H69Sc, 2359) which coincide 
with approximately 15–25% shift in respective transcrip-
tomes (Supplementary Fig. 3A). In order to better define the 
mesenchymal, epithelial and stem cell-like features of NCI-
H69 and its derivatives, their transcriptomic data were com-
pared with that of MSC and type II AEC. Especially, H69Sc 
characterized by a molecular signature harboring both MSC 
and epithelial assets (Fig. 1e and Supplementary Fig. 3B). 
Expression of the genes associated with pluripotency, epi-
thelial-to-mesenchymal transition, and migratory processes 
(POSTN, VCAM1, GLI2, GJA1, ZEB1, FZD7, CD90, DDR2, 
MEIS1, TCF4, TWIST1, EDIL3) were commonly and highly 
upregulated in H69Sc, MSC and in H69Adh to some extent 
(Fig. 1f). Moreover, the differentiation capacity of H69Adh 
and H69Sc cells into osteocyte and chondrocyte lineages 
confirmed their stem-like properties. Adipogenic differentia-
tion could only be induced in H69Adh to a limited extend 
(Fig. 1g). Similar results were also obtained with H82Adh 
cells. All parental SCLC cell lines as well as NCI-H69 
were reluctant to differentiate (data not shown and Fig. 1g). 
Moreover, a pilot in vivo experiment demonstrated the tumor 
propagation capacity of H69Adh cells at lower numbers than 
the parental NCI-H69 cell line (Supplementary Fig. 4).
Both mesenchymal and stem-like assets of tumor cells 
have been associated with increased metastatic potential in 
many cancers besides SCLC [35, 36]. In accordance with 
the literature, we showed that SCLC cells which metasta-
size into the lymph nodes, but not the primary tumor tis-
sues, were highly positive for CD44 (Supplementary Fig. 5). 
Collectively, adherent  CD44+CD90+ cells were identified 
as a CSC-like subpopulation among SCLC cells. Their 
mesenchymal and stem-like characteristics together with 
cytoskeletal features and migratory capacity corresponded to 
the  CD44+ tumor cells’ enrichment in the metastatic lymph 
nodes.
Cytotoxic T lymphocyte (CTL) responses are 
maintained by SCLC cells
Our findings in SCLC tumors, which are in agreement with 
the literature, indicated that the  CD44+ cells with mesen-
chymal and stem-like characteristics tend to metastasize to 
lymph nodes where they frequently encounter T lymphocytes 
[37–39]. Moreover, primary SCLC tumors are rarely infil-
trated by T cells [40] (Supplementary Fig. 6). Therefore, we 
examined the influence of the SCLC cells on CTL-associ-
ated immune reactions. For this purpose, the SCLC cell lines 
and their derivatives were co-cultured with CD3-stimulated 
PBMC. In general, unlike anticipated, the presence of SCLC 
cells did not directly interfere with T cell activation. Intrigu-
ingly, certain parameters tested were even improved by the 
adherent populations, primarily H69Sc. Especially, the 
percentage of  CD8+ T cells expressing the activation mark-
ers CD25, 4-1BB, and CD69 were significantly increased 
in co-cultures with H69Sc cells (Fig. 2a, Supplementary 
Fig. 7). Similarly, indicators of cytotoxic activity includ-
ing secreted perforins and degranulation  (CD107a+ %) were 
augmented upon co-culture with H69Sc (Fig. 2b, Supple-
mentary Fig. 7). H82Adh and H69Adh cells positively influ-
enced the expression of perforin and CD107a by T cells in 
the co-cultures. Even though  CD8+ T cell proliferation was 
noticeably augmented by the adherent SCLC populations 
(with H82Adh, 80.37 ± 5.82%; H69Adh, 90.07 ± 2.55%; 
H69Sc, 90.56 ± 1.85%), induced proliferation was also 
found in the co-cultures with parental SCLC cell lines, 
especially with NCI-H69 (65.15 ± 6.05%) and NCI-H82 
(71.58 ± 6.7%) (Fig. 2c, Supplementary Fig. 7). The amount 
of IFN-γ (PBMC only, 16.5 ng/mL; with SCLC cells, range 
61–114 ng/mL) and IL-2 (PBMC only, 166.24 pg/mL; with 
SCLC cells, range 311.08–441.78 pg/mL), but not TNF-α, 
secreted into the co-cultures were accordingly increased 
with all the SCLC cell types employed (Fig. 2d). Among 
the parental SCLC cell lines, NCI-H82 tend to induce higher 
CD69 expression, perforin secretion, proliferation, and 
IFN-γ production by T cells (Fig. 2a–d).
Together, SCLC cells did not directly hamper cytotoxic T 
cell responses. Intriguingly, H69Sc and also adherent popu-
lations even simulated the T cell activation, proliferation, 
cytotoxicity, and IFN-γ secretion.
PD‑1 ligands are highly upregulated by adherent 
SCLC populations in response to immune responses
Since IFN-γ was the most prominent cytokine produced in 
the co-cultures established with the SCLC cells and PBMC, 
next, the cells were treated with IFN-γ and the discrepan-
cies between the parental SCLC cells and their adherent and 
stem-like derivatives were assessed. In response to IFN-γ, 
enhanced expression of the genes responsible for inflamma-
tory responses and immune signaling pathways were noted 
especially in H69Adh cells and, to a lesser extent, in H69Sc 
cells (Fig.  3a). Correspondingly, IFN-γ response genes 
were explicitly upregulated in H69Adh and H69Sc cells, 
which indicated enhanced responsiveness and/or sensitiv-
ity of these cells to IFN-γ. Expression of the genes impli-
cated in homeostatic and metabolic processes was generally 
augmented in H69Adh. In response to IFN-γ, the pathways 
related to cell adhesion and migration tend to decrease in 
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H69Sc. Nevertheless, the highest expression levels of ATP-
binding cassette (ABC) transporters and the genes involved 
in tryptophan metabolism were observed in the adherent 
H69 subpopulations, particularly in H96Sc (Fig. 3a).
Saliently, PD-L1 and PD-L2 were among the immune 
regulatory genes induced by IFN-γ. All SCLC lines used 
tended to increase the expression of PD-L1 upon exposure to 
IFN-γ. H69Adh and H69Sc highly upregulated both ligands 
at the mRNA level (Fig. 3b). Surface expression of PD-1 
ligands, especially PD-L1, was augmented when the SCLC 
cells were either stimulated with IFN-γ or co-cultured with 
anti-CD3-activated PBMC (Fig. 3c, d). As observed at the 
gene expression level, the highest percentages of PD-L1+ 
and PD-L2+ cells were observed in the adherent popula-
tions of SCLC. Notably, in the absence of stimulation, a sub-
population of H69Sc cells constitutively expressed the PD-1 
ligands (PD-L1+, 26.65 ± 4.23%; PD-L2+, 29.67 ± 8.87%) 
(Fig. 3c, d). In response to IFN-γ,  CD44+ and/or  CD90+ 
subpopulations were identified with higher levels of PD-L1 
and PD-L2 (Supplementary Fig. 8). Moreover, neutraliza-
tion of the IFN-γ secreted into the co-cultures by PBMC 
significantly hindered the upregulation of PD-L1, but not 
PD-L2, on SCLC cells. However, induction of PD-L1 upon 
co-culturing with PBMC was not alleviated on H69Sc cells 
by IFN- γ neutralization (Fig. 3e, f). Therefore, upon expo-
sure to immune responses, the SCLC cells with mesenchy-
mal and stem-like properties displayed enhanced capacities 
to upregulate co-inhibitory ligands, especially through IFN-
γ-mediated pathways.
Activated T cells become prone to checkpoint 
inhibition by mesenchymal and stem‑like SCLC 
subpopulations
Next, in the co-cultures of anti-CD3-stimulated PBMC 
and SCLC cells, wherein T cell responses were not directly 
Fig. 2  Cytotoxic T cell responses in the presence of SCLC cells. 
PBMCs were co-cultured with SCLC cells at 1:0.25 ratio in the pres-
ence of anti-CD3 mAb. Expression of a activation markers CD25, 
4-1BB, and CD69 (n ≥ 4), and b cytotoxicity-related CD107a and 
perforin molecules upon 24 h of the co-culturing (n ≥ 7) was assessed 
by flow cytometry-based techniques. c Proliferation of  CD8+ T cells 
and d secretion of IL-2, IFN-γ, and TNF-α cytokines were deter-
mined after 96 h of the co-culturing (n ≥ 6). (PBMC, control PBMC 
alone; SCLC-21H, 21H; NCI-H82, H82; NCI-H69, H69; *p < 0.05, 
**p < 0.01)
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suppressed, the expression of co-inhibitory receptors 
was assessed on CTLs. Following 96 h of co-culturing, 
the expression of PD-1, CTLA-4, TIM-3, and LAG3 was 
measured on CD8 + T cells (Fig. 4a). Especially when co-
cultured with the adherent derivatives of NCI-H82 and 
NCI-H69 cells, the percentage of cells expressing these 
checkpoint receptors PD-1, CTLA-4, and LAG3 consti-
tuted at 30–40% of the CTLs. TIM-3 was upregulated by a 
larger fraction (> 60%) of CTLs. Intriguingly, the amount 
of PD-1+ (75.64 ± 7.69%),  LAG3+ (77.35 ± 10.03%), and 
TIM-3+ (71.42 ± 3.63%) T cells was significantly increased 
when co-cultured with  CD44+CD90+ H69Sc cells (Fig. 4a, 
Supplementary Fig. 7). In order to understand whether the 
induction of inhibitory receptor expression on CTLs was 
through soluble factors or a cell-contact dependent mecha-
nism, conditioned media (CM) from different subpopula-
tions were applied to co-cultures of NCI-69 cell line and its 
subpopulations (H69Adh and  CD44+CD90+ H69Sc cells) 
with CTLs. Even though CM from  CD44+CD90+ H69Sc 
cells induced TIM-3 expression on CTLs co-cultured with 
NCI-69 or H69Adh to some extent, LAG3 expression was 
not impacted by soluble factors (Fig. 4b). This finding 
evinced the need for cell-contact of stem-like SCLC cells to 
fully maintain their capacity to induce checkpoint receptor 
expression on CTLs. Correspondingly, positivity for these 
co-inhibitory receptors was also detected on the T cells infil-
trating the metastatic foci in the SCLC patients’ lymph node 
samples, especially with common LAG3 positivity (Fig. 4c). 
Next, the  CD8+ T cells (which were also positive for PD-1) 
were isolated from the 96 h co-cultures with H69Sc cells 
according to TIM-3 and LAG3 expression. The mediators 
related to effector functions of the expression profile of 
TIM-3+LAG3+ CTLs were significantly higher than that 
of the TIM-3−LAG3− population (Fig. 4d). Accordingly, 
TIM-3+LAG3+ CTLs were able to more efficiently prolifer-
ate when isolated from the co-cultures (Fig. 4e). In conclu-
sion, upon 96 h of co-culture with H69Sc cells, activated 
and TIM-3+ LAG-3+ expressing CTLs exert effector func-
tions with clonal expansion and elevated pro-inflammatory 
cytokine secretion compared to TIM-3− LAG-3− CTLs 
possessing rather naïve-T cell characteristics (Fig. 4d, e, 
Supplementary Fig. 9). However, if the coculture is extended 
for a further 96 h, proliferation capacity of TIM-3+LAG3+ 
CTLs was significantly impaired by having even fewer pro-
liferated cells than TIM-3−  LAG3− cells upon anti-CD3/
CD28 activation (Fig. 4e, Supplementary Fig. 9). Secretion 
of pro-inflammatory IFN-γ cytokine in response to a second 
activation after 192 h of H69Sc co-culture was hampered 
for both TIM-3+LAG3+ and TIM-3−LAG3− CTLs (Fig. 4f). 
Strikingly, secretion of IFN-γ from TIM-3+LAG3+ CTLs 
decreased up to 2.26 ng/mL after 192 h of co-culture with 
H69Sc while the level was above 50 ng/mL when TIM-
3+LAG3+  CD8+ T cells were stimulated after 96 h H69Sc 
co-culture. The alteration in the functional state of CTLs 
over time in SCLC co-culture with induction of multiple 
inhibitory receptor expression indicates T cell exhaustion 
and suppression in response to CSC subpopulation of SCLC.
In our experimental setting, since the inhibitory ligands, 
especially PD-L1 and PD-L2, were upregulated by SCLC 
cells following the IFN-γ-related immune reactions and the 
co-inhibitory receptors were upregulated on the CTLs; next, 
we sought if effector T cell responses are functionally hin-
dered upon further interaction. For this purpose, the SCLC 
cells were pretreated with IFN-γ in order to induce immune 
regulatory pathways and co-cultures were again established 
with anti-CD3-activated PBMC or  CD8+ T cells. In com-
parison with the PBMC cultured with control SCLC cells 
without IFN-γ pretreatment, IFN-γ-treated H69Sc cells 
reduced the CTL proliferation and cytolytic activity of CTLs 
approximately by 25% (Fig. 4g, h). Even though CTL prolif-
eration was not modulated with other SCLC cells and their 
adherent derivatives, cytolysis of H82Adh and H69Adh cells 
was moderately reduced when these cells were treated with 
IFN-γ prior to co-culturing (Fig. 4g, h).
Collectively, upon interaction with the SCLC subpopu-
lations bearing CSC-like and mesenchymal properties, the 
cytotoxic T cells can display effector functions including 
IFN-γ secretion and cytotoxicity; however, they also highly 
upregulate inhibitory checkpoint receptors and become 
prone to suppressive signals. Our data indicate the regula-
tory roles of CSC-like SCLC cells especially in the meta-
static lymph nodes where SCLC cells inevitably interact 
with T cells.
Discussion
SCLC demonstrates optimal first-line therapy responses; 
however, many patients succumb to the disease in a rather 
short period of time [4, 5]. The poor survival of SCLC 
patients is due to the tumor cells’ heterogeneity, the recur-
rence with inevitable drug resistance and distant metastasis 
capacity which are all linked to CSC in many other tumor 
types as well [11]. Candidate subpopulations with CSC 
Fig. 3  IFN-γ response and PD-1 ligand expression in SCLC subpopu-
lations. a Percent enrichment analysis comparing the pathways modu-
lated among NCI-H69 and its subpopulations after IFN-γ stimulation. 
b Relative change in the gene expression of PD-L1 and PD-L2 in the 
SCLC cells is presented as heatmaps. c Percentage distribution and 
d representative flow cytometry histograms of PD-L1+ and PD-L2+ 
SCLC cells under control conditions, after IFN-γ stimulation (150 ng/
mL) for 48 h, or co-culturing with anti-CD3-stimulated PBMCs for 
72  h. e The percentages and f representative flow cytometry his-
tograms of PD-L1 and PD-L2 positivity on SCLC cells when co-
cultured for 24  h with anti-CD3-primed PBMCs in the presence of 
IFN-γ blocking mAb or isotype-matched control mAb. (SCLC-21H, 
21H; NCI-H82, H82; NCI-H69, H69; n ≥ 3, *p < 0.05, **p < 0.01)
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features such as insensitivity to toxic materials, invasive-
ness, 3D growth and tumorigenicity at low numbers were 
previously reported in primary small cell lung tumors and 
cell lines. Adherence and expression of common stem cell 
markers CD44, CD90, CD87, and CD133 have been used 
for the identification of CSC [9, 33, 41–43]. We charac-
terized the adherent subpopulations after serial passaging 
in NCI-H82 and NCI-H69 cell cultures. The adherent sub-
populations showed greater surface area on fibronectin with 
significantly elevated directionality in H69Adh and induced 
tumor propagation capacity in nude mice. In terms of marker 
expression, common CD90 expression in SCLC cell lines 
and subpopulations suggested that CD90 is not a reliable 
CSC marker alone for SCLC. However, together with CD44 
expression in adherent H69Sc, it augmented the migratory 
capacity of the cells and resembled the transcriptomic profile 
of MSC, especially in terms of the genes related to pluripo-
tency, epithelial-to-mesenchymal transition, and migration. 
Here,  CD44+CD90+ adherent SCLC cells were character-
ized and used as a prototype for CSC in SCLC. As MSCs 
possess the potential to promote metastasis by downregulat-
ing antitumor immune responses [35, 36], the presence of 
 CD44+ SCLC cells was of abundance and in close contact 
with lymphocytes in the metastatic lymph nodes although 
they were scarce in primary tumors. Furthermore, the evi-
dences such as the unique adaptive immune resistance mech-
anism emerged from CD44 expressing cells in squamous cell 
carcinoma (SCC) and positive correlation of CD44 express-
ing cell number with the tumor progression and relapse in 
SCLC support the potential role of CD44 expressing SCLC 
cells in tumor progression by developing adaptive resistance 
to immune destruction [23, 44]. Hence, characterization of 
immunomodulatory potential of  CD44+CD90+ adherent 
SCLC cells offers a clinically relevant disease progression 
perspective in SCLC including a new candidate population 
for immunotherapy.
The immune system is programmed to discriminate and 
target non-self and stressed cells including tumor cells which 
possess altered-self antigen repertoire [45, 46]. SCLC is con-
sidered an immunogenic tumor type with its high mutation 
burden and common paraneoplastic syndromes observed 
in the patients [30, 31]. However, as also observed in our 
study, leukocyte and T lymphocyte infiltration are limited 
in primary SCLC lesions [40]. To our knowledge, immune 
modulation in the areas of metastasis is poorly understood; 
a dynamic model should be employed to better follow how T 
cell-mediated anti-tumor immune responses are regulated in 
the presence of SCLC cells, i.e. potentially CSC-like  CD44+ 
fraction. By using a co-culture model, our study recapitulates 
the interaction between immune cells, especially CTLs, and 
the subpopulations of SCLC cells. Unlike many tumor cells 
of various tissue origins, SCLC cells did not directly sup-
press CTL responses. Compared to the leukocytes cultured 
alone, the in vitro milieu in the co-cultures even contributed 
to the augmentation of CTL-associated immune parameters. 
Nevertheless, the CSC-like subpopulations with mesenchy-
mal properties showed the highest capacity to promote acti-
vation, proliferation, cytotoxicity and IFN-γ secretion. This 
intriguing situation has been previously implied by other 
studies performed on acute myeloid leukemia, basal-like 
breast cancer, and melanoma. As a common feature, these 
cancer types generally display conspicuous infiltration by T 
lymphocytes. This phenomenon has been described as an 
adaptive (secondary) immune resistance mechanism where 
the cancer cells start a suppression program via induction of 
regulatory molecule expression upon exposure to inflamma-
tory mediators, such as IFN-γ [24, 25, 47].
With its cytostatic, cytotoxic, and immune-provoking 
effects, IFN-γ is one of the central mediators of anti-tumor 
immunity. As summarized before [26], three strategies are 
utilized by tumor cells to cope with the anti-tumor effects of 
IFN-γ: i) losing the sensitivity to IFN-γ, ii) shifting the sign-
aling pathway from STAT1/IRF1 to rather pro-tumorigenic 
alternative pathways like STAT3/NF-κB, iii) up-regulation 
of inhibitory ligands such as PD-L1 and PD-L2. Only lim-
ited PD-L1 expression has been reported in SCLC cell lines 
and patient samples [48, 49]. Correspondingly, in non-small 
cell lung cancer (NSCLC), the absence of PD-L1 expression 
on tumor cells was associated with impaired IFN-γ response 
[50]. Considering the significant elevation of IFN-γ in the 
co-cultures of SCLC cells with activated immune cells, the 
transcriptome data and induction of PD-1 ligands indicate 
that particularly adherent or CSC-like subpopulations in 
Fig. 4  Expression of inhibitory receptors and the functional status of 
T cells co-cultured with SCLC cells. a Expression of PD-1, CTLA-
4, TIM-3 and LAG3 on  CD8+ T cells in the co-cultures of PBMCs 
and SCLC subpopulations. The cultures were established in the pres-
ence of anti-CD3 mAb (25 ng/mL) for 96 h at a 0.25:1 SCLC:PBMC 
ratio. b Relative expression change of TIM-3 and LAG3 on  CD8+ T 
cells in the co-cultures of PBMCs and SCLC subpopulations treated 
with conditioned media collected from different subpopulations in 1:1 
ratio. The cultures were established in the presence of anti-CD3 mAb 
(25 ng/mL) for 96 h at a 0.25:1 SCLC:PBMC ratio with CM collected 
after 48 h of cell culture. c Representative LAG3, PD-1 and TIM-3 
immunohistochemical staining micrographs with checkpoint recep-
tor expressing lymphocytes positive tumor-draining lymph node per-
centage in SCLC patients (magnification, 400x). TIM-3−LAG3− and 
TIM-3+LAG3+  CD8+ T cells were purified from the 96 h or 192 h 
co-culturing of PBMCs and H69Sc cells, d cytokines produced were 
assessed by a flow cytometric bead array following 16 h stimulation 
with PMA and ionomycin upon 96  h, e proliferation capacity was 
assessed by CFSE dilution upon 72 h stimulation with anti-CD3 and 
anti-CD28 mAbs, f secreted IFN-γ amount with 16 h stimulation with 
PMA and ionomycin. CFSE-labelled PBMCs were co-cultured with 
IFN-γ-pretreated or control SCLC cells; the change g in CTL prolifer-
ation for 96 h and h CD3/CD28 dynabeads activated CTL co-cultured 
with IFN-γ-pretreated or control SCLC cells in SCLC cell lysis for 
72 h was calculated. (PBMC, control PBMC alone; SCLC-21H, 21H; 
NCI-H82, H82; NCI-H69, H69; n ≥ 3, *p < 0.05, **p < 0.01)
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SCLC respond to IFN-γ. Of note, these subpopulations are 
represented at very small numbers among (parental) SCLC 
cells; therefore, their impact on immune modulation is gen-
erally underscored.
Upon exposure to immune reactions which lead to the 
production of a plethora inflammatory mediators into the co-
cultures, IFN-γ was determined the major factor that induced 
PD-L1, but not PD-L2. Apart from IFN-γ, numerous inflam-
matory factors were reported to have PD-L1 induction 
capacity including TNF-α, IL-1α, IL-17, IL-6, IL-8, EGF, 
IL-4, IL-27 and IL-10 [51, 52]. Similar to having various 
inducer factors, STAT1 is not the only transcription factor 
for PD-L1 expression. Pro-tumorigenic transcription factors 
such as Stat3, Myc, Kras that are also mediated with vari-
ous inflammatory factors also play in role on PD-L1 expres-
sion [52]. Conversely, regulation of PD-L2 differed from 
PD-L1 by being regulated more through Th2 cytokines and 
Stat6 or NF-κB transcription factors if not induced through 
IFN-γ [53, 54]. Particularly, PD-L1 and PD-L2 expression 
in  CD44+CD90+ CSC-like H69Sc cells were potentially sen-
sitive to other inflammatory factors as well. This observa-
tion supports the notion that stem cells and CSCs are more 
adjustable to changing conditions and inflammation [55, 56]. 
Thus, SCLC cells and more explicitly CSC subpopulations 
show the signatures of adaptive resistance to better cope 
with anti-tumor immunity [24, 25].
Following activation, T cells upregulate inhibitory 
receptors that would hinder excessive responses and avoid 
immune-related pathologies [57, 58]. In the co-cultures, 
wherein the presence of SCLC cells did not impair CTL acti-
vation, inhibitory PD-1, CTLA-4, TIM-3, and LAG3 recep-
tor expression were enhanced on the CTLs. This observation 
was in accordance with metastasis-infiltrating lymphocytes 
positive for PD-1, TIM-3, or LAG3. Therefore, in terms 
of PD-1 ligands, the upregulation of their cognate recep-
tor would initiate a cycle of suppression. We did not test 
the expression of ligands for the inhibitory receptors other 
than PD-1; nevertheless, transcriptomic analyses indicated a 
negligible expression of the ligands for CTLA-4, TIM-3, and 
LAG3 on SCLC cells. Even though there was no evidence to 
claim the upregulated expression of ligands for alternative 
checkpoints such as TIM-3 and LAG3 on stem-like subpopu-
lation of SCLC cells, the expression of these ligands such 
as Galectin-3 and Galectin-9 are regulated by inflammatory 
cytokines such as IFN-γ thus widely expressed on immune 
cells together with LAG3 ligand HLA-DR expression on 
monocytes/macrophages [59–61]. Hence, the presence of 
inhibitory ligands needs to be evaluated in the primary 
tumors and metastatic specimens of SCLC patients since 
expression of these ligands are also commonly found on 
stromal cells such as myeloid-originated immune cells.
High-level expression of multiple inhibitory recep-
tors such as PD-1, LAG3 and TIM-3 on CTLs have 
been associated with a hyporesponsive state in which 
anti-tumor responses become ineffective. However, PD-
1+LAG3+TIM-3+ CTLs were identified with potent effec-
tor functions, secretion of soluble mediators and prolifera-
tion. Therefore, CSC-like H69Sc cells did not induce T cell 
exhaustion which was examined as a further mechanism used 
by immunogenic tumors to hinder immunity. On the other 
hand, the functional status of CTLs infiltrating the lymph 
node metastases of SCLC must be further investigated.
In conclusion, SCLC cells did not directly interfere with 
CTL responses and CSC-like adherent subpopulations, 
which are harbored by SCLC cells in very small numbers, 
can even provide appropriate milieu maintaining the T cell 
activation but induce the expression of inhibitory recep-
tors. Thus, in their first encounter with SCLC cells, T cells 
may become activated, inducing their cytotoxic functions 
resulting in the death of SCLC cells. However, with chronic 
inflammation, our results determine a possible T cell exhaus-
tion due to elevation of inhibitory receptor expression on 
CTLs together with possibly sustained activation signal 
and elevated inhibitory ligands in the environment (Fig. 5). 
Moreover, the adaptive resistance capacity of CSC-like 
SCLC cells in response to inflammatory mediators, espe-
cially IFN-γ, makes them less immunogenic through upregu-
lation of PD-1 ligands (Fig. 5). It must be noted that, due 
to the immune exclusion in the primary tumor, this encoun-
ter is more likely to happen in metastatic sites including 
lymph nodes. An increased number of  CD44+ SCLC found 
in advanced disease in addition to CD44 enrichment in meta-
static lymph nodes support this theory. Even though PD-1/
PD-L1 interaction inhibits T cell proliferation and killing to 
some extent, T cells become open for immune suppression 
with the common expression of multiple inhibitory recep-
tors. In other words, targeting one checkpoint pathway might 
be overcome with the suppression signal from an alternative 
checkpoint receptor. This finding is consistent with the lim-
ited success of α-PD-1/PD-L1 therapies in SCLC patients 
and indicates a potential requirement of multiple targeting. 
Therefore, the CSC-like subpopulation in SCLC which cor-
relates with metastatic potential and drug resistance may 
serve as a preferential target for combination checkpoint 
blockade immunotherapy.
Conclusion
Cancer stem cells were identified as modulatory cells in 
acquiring therapy resistance and cancer progression in 
SCLC patients. Moreover, mesenchymal CSC-like SCLC 
cells displayed an immune-provoking impact on cyto-
toxic T lymphocytes which led to the upregulation of co-
inhibitory receptors on CTLs thus T cell exhaustion upon 
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prolonged activation. In response to CTL activation and 
IFN-γ secretion, CSC-like SCLC cells induced PD-L1 and 
PD-L2 expression to further limit the CTL responses. A 
better understanding of this immunomodulatory mecha-
nism regulated by CSC-like cells might have an impact 
on novel cancer immunotherapy approaches for SCLC 
patients.
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Fig. 5  Schematic demonstration of the outcomes of CTL interac-
tion with SCLC cells, primarily CSC-like subpopulation.  CD44+ 
 CD90+ CSC-like subpopulation of SCLC possessing mesenchymal 
features with elevated migration and lymphatic metastasis capacity 
(1) induces CTL activation, proliferation, cytotoxicity including high 
amount of IFN-γ secretion together with expression of checkpoint 
receptors on CTLs. (2) IFN-γ secreted by CTLs regulates phenotype, 
signaling and metabolism of the CSC-like subpopulation of SCLC 
cells with (3) augmented expression of PD-1 ligands indicating the 
adaptive resistance capacity of these cells. (4) Eventually, sustained 
inflammation and elevation of regulatory ligands in the environment 
result with T cell exhaustion that impairs proliferation capacity and 
cytotoxicity of CTLs
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